New Drug R&D

Ambrisentan Tablets

Product Name: Ambrisentan Tablets
Dosage Forms: Tablet
Strengths: 5 mg, 10 mg
Mechanism of Action:
Endothelin-1 (ET-1) may play a critical role in the pathogenesis and progression of PAH. Two receptor subtypes, ETA and ETB, mediate the effects of ET-1 in the vascular smooth muscle and endothelium. The primary actions of ETA are vasoconstriction and cell proliferation, while the predominant actions of ETB are vasodilation, antiproliferation, and ET-1 clearance. Ambrisentan is a high-affinity ETA receptor antagonist with a high selectivity for the ETA versus ETB receptor (>4000-fold). The clinical impact of high selectivity for ETA is not known.
It is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1):
• To improve exercise ability and delay clinical worsening.
• In combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability.
Processing Number: CXHS1400158, CYHS1400695, CYHS1400696
Status: Has gotten the clinical trial permission (2016L01627, 2016L01519, 2016L01515) in January, 2016.
Copyright @ Beijing Hope Pharmaceutical Co., Ltd.